CN118955490A - O-糖蛋白-2-乙酰氨基-2-脱氧-3-d-吡喃糖苷酶抑制剂 - Google Patents
O-糖蛋白-2-乙酰氨基-2-脱氧-3-d-吡喃糖苷酶抑制剂 Download PDFInfo
- Publication number
- CN118955490A CN118955490A CN202410813893.5A CN202410813893A CN118955490A CN 118955490 A CN118955490 A CN 118955490A CN 202410813893 A CN202410813893 A CN 202410813893A CN 118955490 A CN118955490 A CN 118955490A
- Authority
- CN
- China
- Prior art keywords
- compound
- optionally substituted
- pharmaceutically acceptable
- acceptable salt
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862642932P | 2018-03-14 | 2018-03-14 | |
| US62/642,932 | 2018-03-14 | ||
| US201862690536P | 2018-06-27 | 2018-06-27 | |
| US62/690,536 | 2018-06-27 | ||
| US201862699443P | 2018-07-17 | 2018-07-17 | |
| US62/699,443 | 2018-07-17 | ||
| PCT/US2019/021995 WO2019178191A1 (en) | 2018-03-14 | 2019-03-13 | O-glycoprotein-2-acetamido-2-deoxy-3-d-glycopyranosidase inhibitors |
| CN201980019170.5A CN112218863B (zh) | 2018-03-14 | 2019-03-13 | O-糖蛋白-2-乙酰氨基-2-脱氧-3-d-吡喃糖苷酶抑制剂 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201980019170.5A Division CN112218863B (zh) | 2018-03-14 | 2019-03-13 | O-糖蛋白-2-乙酰氨基-2-脱氧-3-d-吡喃糖苷酶抑制剂 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN118955490A true CN118955490A (zh) | 2024-11-15 |
Family
ID=65952097
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202410813893.5A Pending CN118955490A (zh) | 2018-03-14 | 2019-03-13 | O-糖蛋白-2-乙酰氨基-2-脱氧-3-d-吡喃糖苷酶抑制剂 |
| CN201980019170.5A Active CN112218863B (zh) | 2018-03-14 | 2019-03-13 | O-糖蛋白-2-乙酰氨基-2-脱氧-3-d-吡喃糖苷酶抑制剂 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201980019170.5A Active CN112218863B (zh) | 2018-03-14 | 2019-03-13 | O-糖蛋白-2-乙酰氨基-2-脱氧-3-d-吡喃糖苷酶抑制剂 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230117898A1 (cg-RX-API-DMAC10.html) |
| EP (2) | EP3765458B1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP7453916B2 (cg-RX-API-DMAC10.html) |
| CN (2) | CN118955490A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2019234759C1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3093315A1 (cg-RX-API-DMAC10.html) |
| ES (1) | ES2942211T3 (cg-RX-API-DMAC10.html) |
| MA (1) | MA52004A (cg-RX-API-DMAC10.html) |
| MX (1) | MX2020009530A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2019178191A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018223192A1 (en) * | 2017-02-27 | 2019-06-20 | Janssen Pharmaceutica Nv | [1,2,4]-triazolo [1,5-a]-pyrimidinyl derivatives substituted with piperidine, morpholine or piperazine as OGA inhibitors |
| CN113166137B (zh) | 2018-09-19 | 2024-08-16 | 比奥根Ma公司 | O-糖蛋白-2-乙酰氨基-2-脱氧-3-d-吡喃葡萄糖苷酶抑制剂 |
| WO2021094312A1 (en) | 2019-11-11 | 2021-05-20 | Janssen Pharmaceutica Nv | Pyrrolidine and bicycloheteroaryl containing oga inhibitor compounds |
| WO2021110656A1 (en) | 2019-12-02 | 2021-06-10 | Janssen Pharmaceutica Nv | Oga inhibitor compounds |
| KR20220118484A (ko) | 2019-12-18 | 2022-08-25 | 얀센 파마슈티카 엔.브이. | Oga 억제제 화합물 |
| WO2021123291A1 (en) | 2019-12-18 | 2021-06-24 | Janssen Pharmaceutica Nv | Oga inhibitor compounds |
| AU2020409728A1 (en) | 2019-12-18 | 2022-08-11 | Janssen Pharmaceutica Nv | OGA inhibitor compounds |
| KR102533471B1 (ko) | 2020-11-23 | 2023-05-19 | (주) 메디프론디비티 | O-GlcNAcase 저해 활성을 갖는 화합물 및 이의 용도 |
| CN114213315A (zh) * | 2021-12-31 | 2022-03-22 | 上海陶术生物科技有限公司 | 含氮杂环类化合物及其中间体的合成方法 |
| CN114560805B (zh) * | 2022-01-20 | 2024-11-29 | 上海陶术生物科技有限公司 | 含氮杂环化合物及其中间体的合成方法 |
| CN121405694A (zh) * | 2024-07-26 | 2026-01-27 | 浙江同源康医药股份有限公司 | Oga抑制剂及其应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
| WO2013075084A1 (en) | 2011-11-18 | 2013-05-23 | Constellation Pharmaceuticals | Modulators of methyl modifying enzymes, compositions and uses thereof |
| US9206128B2 (en) | 2011-11-18 | 2015-12-08 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| WO2013078320A1 (en) | 2011-11-21 | 2013-05-30 | Constellation Pharmaceuticals | Modulators of methyl modifying enzymes, compositions and uses thereof |
| US9085583B2 (en) | 2012-02-10 | 2015-07-21 | Constellation—Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| PL2953941T3 (pl) | 2013-02-11 | 2017-11-30 | Constellation Pharmaceuticals, Inc. | Modulatory enzymów modyfikujących metyl, ich kompozycje i zastosowania |
| WO2014159234A1 (en) * | 2013-03-14 | 2014-10-02 | Merck Patent Gmbh | Glycosidase inhibitors |
| US9745305B2 (en) | 2013-03-15 | 2017-08-29 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| US9969716B2 (en) | 2013-08-15 | 2018-05-15 | Constellation Pharmaceuticals, Inc. | Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof |
| WO2017106254A1 (en) * | 2015-12-18 | 2017-06-22 | Merck Sharp & Dohme Corp. | Glycosidase inhibitors and uses thereof |
| EP3555094A1 (en) * | 2016-12-16 | 2019-10-23 | Janssen Pharmaceutica NV | Bicyclic oga inhibitor compounds |
| EP3555087A1 (en) * | 2016-12-16 | 2019-10-23 | Janssen Pharmaceutica NV | Monocyclic oga inhibitor compounds |
| AU2018223192A1 (en) * | 2017-02-27 | 2019-06-20 | Janssen Pharmaceutica Nv | [1,2,4]-triazolo [1,5-a]-pyrimidinyl derivatives substituted with piperidine, morpholine or piperazine as OGA inhibitors |
-
2019
- 2019-03-13 EP EP19713945.4A patent/EP3765458B1/en active Active
- 2019-03-13 MA MA052004A patent/MA52004A/fr unknown
- 2019-03-13 ES ES19713945T patent/ES2942211T3/es active Active
- 2019-03-13 MX MX2020009530A patent/MX2020009530A/es unknown
- 2019-03-13 JP JP2020548963A patent/JP7453916B2/ja active Active
- 2019-03-13 CA CA3093315A patent/CA3093315A1/en active Pending
- 2019-03-13 EP EP23151036.3A patent/EP4186899A1/en active Pending
- 2019-03-13 WO PCT/US2019/021995 patent/WO2019178191A1/en not_active Ceased
- 2019-03-13 CN CN202410813893.5A patent/CN118955490A/zh active Pending
- 2019-03-13 AU AU2019234759A patent/AU2019234759C1/en active Active
- 2019-03-13 CN CN201980019170.5A patent/CN112218863B/zh active Active
-
2022
- 2022-08-24 US US17/894,461 patent/US20230117898A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP7453916B2 (ja) | 2024-03-21 |
| WO2019178191A1 (en) | 2019-09-19 |
| JP2021518340A (ja) | 2021-08-02 |
| MX2020009530A (es) | 2021-01-15 |
| ES2942211T3 (es) | 2023-05-30 |
| AU2019234759C1 (en) | 2025-02-06 |
| AU2019234759A1 (en) | 2020-09-17 |
| EP3765458B1 (en) | 2023-01-11 |
| WO2019178191A8 (en) | 2019-12-26 |
| MA52004A (fr) | 2021-01-20 |
| US20230117898A1 (en) | 2023-04-20 |
| CN112218863B (zh) | 2024-07-12 |
| CA3093315A1 (en) | 2019-09-19 |
| CN112218863A (zh) | 2021-01-12 |
| EP3765458A1 (en) | 2021-01-20 |
| EP4186899A1 (en) | 2023-05-31 |
| AU2019234759B2 (en) | 2024-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112218863B (zh) | O-糖蛋白-2-乙酰氨基-2-脱氧-3-d-吡喃糖苷酶抑制剂 | |
| EP3271352B1 (en) | Piperazine carbamates and methods of making and using same | |
| JP7577655B2 (ja) | 環状尿素 | |
| CN113072542B (zh) | RORγt抑制剂及其制备方法和用途 | |
| CN113166137B (zh) | O-糖蛋白-2-乙酰氨基-2-脱氧-3-d-吡喃葡萄糖苷酶抑制剂 | |
| JP2012532916A (ja) | 特に睡眠障害及び薬物中毒の治療に適したスピロアミノ化合物 | |
| WO2022152852A1 (en) | Antagonists of mrgx2 | |
| MX2014004254A (es) | Derivados de carbamato / urea que contienen anillos de piperidina y piperazina como inhibidores del receptor h3. | |
| US20160039828A1 (en) | Imidazopyridazine Compounds | |
| CN114369095A (zh) | 适用作ssao抑制剂的氨基嘧啶化合物及其制备方法 | |
| EP3891146B1 (en) | Morpholinyl, piperazinyl, oxazepanyl and diazepanyl derivatives useful as o-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors | |
| JP7663503B2 (ja) | アゼチジニルｏ－糖タンパク質－２－アセトアミド－２－デオキシ－３－ｄ－グルコピラノシダーゼ阻害剤 | |
| KR20230083276A (ko) | 오토탁신 억제제 화합물 | |
| US11459324B2 (en) | O-glycoprotein-2-acetamido-2-deoxy-3-D-glycopyranosidase inhibitors | |
| KR20240165360A (ko) | 에모파밀 결합 단백질 억제제 및 이의 용도 | |
| JP2023509496A (ja) | ＲＯＲγｔ阻害剤、その製造方法及び使用 | |
| HK40046057B (en) | O-glycoprotein-2-acetamido-2-deoxy-3-d-glycopyranosidase inhibitors | |
| HK40046057A (en) | O-glycoprotein-2-acetamido-2-deoxy-3-d-glycopyranosidase inhibitors | |
| AU2024332695A1 (en) | Pyrazolyl compounds as emopamil binding protein inhibitors | |
| JP2026514428A (ja) | 高血糖症および高血糖症を特徴とする障害の治療に使用するためのヘテロシクロアルキルベータ－ヒドロキシアルキルアミン |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |